Japanese Journal of Clinical Oncology · 1993 · 15 citations · 0 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyChemotherapyAdverse Effects Of ChemotherapyBreast Cancer PharmacotherapyMetastatic Breast CancerToxicity ManagementBreast Cancer ChemotherapyBreast Cancer Hormonal TherapyBreast Cancer Response AssessmentChemotherapy Response AssessmentComplete Response AssessmentMetastatic Breast Cancer TreatmentPhase Ii Investigation
Seventy metastatic breast adenocarcinoma patients, pretreated with standard hormonotherapy or chemotherapy, received continuous UFT at 10 mg/kg/day, orally, for at least two months. There were one complete response (1.5%), 12 partial responses (17%), one minor response and 37 disease stabilizations. The median duration of response was nine months. A greater efficacy was demonstrated in 29 patients with soft tissue disease, with a rate of 38% objective responses. The major toxicity was gastrointestinal, with 45% of patients developing nausea and vomiting and 30%, diarrhea. Bone marrow toxicity was slight. UFT has shown antitumor activity in our group of pretreated patients, especially these with the cutaneous tumoral and/or inflammatory form of the disease.